Heartflow, Inc. (HTFL) company profile

Heartflow develops artificial intelligence and computational software to provide non-invasive diagnostic and management solutions for coronary artery disease. The company's core offering, the Heartflow Platform, utilizes deep learning and computational fluid dynamics to construct personalized 3D anatomical models of coronary arteries from coronary computed tomography angiography scans. Key offerings include Heartflow RoadMap Analysis, which visualizes anatomy to streamline radiology workflows; Heartflow FFR CT Analysis, which evaluates fractional flow reserve and blood flow restrictions; and Heartflow Plaque Analysis, which characterizes plaque composition and volume. Its customer base consists of hospitals, outpatient imaging centers, and clinicians such as radiologists and cardiologists.

The enterprise maintains an installed base exceeding 1,465 accounts across the United States. Its corporate headquarters are not identified in the provided disclosure. International clinical studies have evaluated the technology across sites in Europe, the United Kingdom, Japan, Korea, Australia, and Canada, while research also references a Dutch study site.

Summary of the business section of Heartflow's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $19.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.